Julio Fernandez-Bombino, MD
Nephrology · Hialeah, FLNPI 1174630479
Payments from drug & device makers
Across 287 payments — averaging $154.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- AstraZeneca$1K
- Bayer$956
- Mallinckrodt Hospital Products Inc.$846
- Vifor Pharma, Inc.$479
- Otsuka America Pharmaceutical, Inc.$337
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,15698%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $38,010 |
| AstraZeneca | 57 | $1,111 |
| Bayer | 40 | $956 |
| Mallinckrodt Hospital Products Inc. | 30 | $846 |
| Vifor Pharma, Inc. | 42 | $479 |
| Otsuka America Pharmaceutical, Inc. | 12 | $337 |
| Ardelyx, Inc. | 13 | $287 |
| Travere Therapeutics, Inc. | 12 | $265 |
| Amgen(2 entities) | 8 | $262 |
| Aurinia Pharma U.S., Inc. | 10 | $228 |
| Boehringer Ingelheim | 8 | $210 |
| Calliditas Therapeutics US Inc. | 9 | $201 |
| GSK | 6 | $171 |
| Lilly USA, LLC | 7 | $167 |
| ANI Pharmaceuticals, Inc. | 4 | $122 |
| Akebia Therapeutics Inc | 5 | $97 |
| OPKO Pharmaceuticals, LLC | 2 | $95 |
| Novartis | 4 | $86 |
| Fresenius USA Marketing, Inc. | 4 | $75 |
| Baxter Healthcare | 2 | $59 |
| Mallinckrodt Enterprises LLC | 2 | $57 |
| Medtronic | 2 | $56 |
| Amarin Pharma, Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Nuwellis, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Merck | 1 | $17 |
How this compares
$44,315 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $215,835 |
| JardianceEmpagliflozin | 170 | $199,841 |
| KerendiaFinerenone | 89 | $105,355 |
| VeltassaPatiromer Calcium Sorbitex | 186 | $99,352 |
| TradjentaLinagliptin | 84 | $90,194 |
| VelphoroSucroferric Oxyhydroxide | 16 | $26,683 |
| LokelmaSodium Zirconium Cyclosilicate | 54 | $20,981 |
| MyrbetriqMirabegron | 17 | $12,906 |
| VascepaIcosapent Ethyl | 25 | $8,166 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,686 |
| Sevelamer Carbonate | 23 | $3,937 |
| Famotidine | 236 | $3,826 |
| Valsartan | 159 | $2,276 |
| Febuxostat | 12 | $1,248 |
| Calcium Acetate | 21 | $945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $210 | $290,035254 claims |
| AstraZenecaFarxiga, Lokelma | $1,111 | $236,816234 claims |
| BayerKerendia | $956 | $105,35589 claims |
| Fresenius USA Marketing, Inc.Velphoro | $75 | $26,68316 claims |
| MerckJanumet | $17 | $5,68611 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $122 | $2,276159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.
Other nephrology in Hialeah
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.